Arvinas (ARVN) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Arvinas (ARVN) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 23.0% versus a loss of 59.0%. Over five years, SPRY leads with a -53.8% price change compared with -91.2% for ARVN. Arvinas is the larger company by market cap ($484.6 million vs $453.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | SPRY |
|---|---|---|
| Share price | $7.51 | $4.56 |
| Market cap | $484.55M | $453.48M |
| 1-day change | +0.81% | +4.59% |
| YTD return | -36.68% | -60.86% |
| 1-year return | -22.97% | -58.96% |
| 5-year return | -91.18% | -53.75% |
| P/E ratio (TTM) | 28.88 | — |
| EPS (TTM) | $0.26 | $-2.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $13.15 |
| 52-week low | $6.97 | $3.99 |
| Distance from 52-week high | -48.24% | -65.32% |
| Analyst consensus | buy | none |
| Avg. price target upside | +85.49% | +393.42% |
| Average volume | 788.21K | 1.86M |
| Shares outstanding | 64.52M | 99.45M |
| Employees | 246 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARVN has outperformed SPRY by 36.0 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
ARVN vs SPRY FAQ
Which is bigger, Arvinas or ARS Pharmaceuticals?
Arvinas (ARVN) is larger, with a market capitalization of $484.55M compared with $453.48M for ARS Pharmaceuticals (SPRY).
Which stock has performed better over the past year, ARVN or SPRY?
ARVN returned -22.97% over the past 12 months, compared with -58.96% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.